CA-QUANTA-CLOUD
15.3.2021 16:02:08 CET | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, announced its growing portfolio of Total Cloud Solutions featuring AMD EPYC™ 7003 Series Processors . QCT systems supporting AMD EPYC™ 7003 series processors help their customers adapt to changing business needs, while offering incredible performance with faster time to results.
Among QCT’s Total Cloud Solutions making their debut is the all-new QuantaGrid D43N-3U server which supports the 3rd Gen AMD EPYC™ processors and provides the highest CPU-GPU ratio in the market.
AMD EPYC™ 7003 Series Processors
Based on the “Zen 3” core architecture, the AMD EPYC™ 7003 Series processors drive a new standard for the modern data center with fantastic performance capabilities. Designed to be the world’s highest performance x86 server processor, it helps companies maximize their investments while providing an attractive data center ROI. AMD also continues to drive x86 security innovation with a group of advanced security features and a silicon embedded security subsystem that helps protect a customer’s most valuable asset – their data.
“We designed the EPYC™ 7003 Series processors to give our customers exactly what they said they needed, performance across all workloads and the ability to drive more time to value, right out of the box,” said Ram Peddibhotla, corporate vice president, EPYC product management, AMD. “With leadership architecture, performance, and modern security features, EPYC™ 7003 Series processors are a superior choice and continue to drive the standard for the modern data center.”
QCT QuantaGrid D43N-3U server
The D43N-3U is a dual-socket server designed to support up to 4 double-width or 8 single-width GPU accelerators without any PCIe switch chips. Not only does this reduce the latency between GPU and CPU, but it allows the system to act as a powerhouse for various disciplines - i.e. HPC, weather forecasting, automotive, AI training and inference, graphic rendering, cloud gaming, etc.
“QCT is always looking to deliver products that meet changing workload needs,” said Mike Yang, President of QCT. “With the QuantaGrid D43N-3U, we worked with our strategic partner, AMD, to deliver innovations that combine all the advantages of the 3rd Gen AMD EPYC processors with our comprehensive designs to allow our customers to arm their data center with the resources to drive performance in a consolidated solution.”
QCT is tapping the full functionality of the AMD EPYC™ 7003 Series processors with more compute, more memory, more expansion possibilities, and more bandwidth between nodes to enable businesses with access to more data resulting in faster answers. Organizations of all sizes can benefit from the innovation and performance breakthroughs EPYC™ 7003 Series processors deliver. QCT also offers other QuantaGrid models that support AMD EPYC™ processors for HPC and more.
For more details visit https://go.qct.io/EPYC .
About Quanta Cloud Technology (QCT)
QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.
Product lines include hyperconverged and software-defined data center solutions as well as servers, storage, switches and integrated racks with an ecosystem of hardware components and software partners. QCT designs, manufactures, integrates and services its offerings via its own global network. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.QCT.io
AMD, the AMD arrow logo, EPYC, and combinations thereof are trademarks of Advanced Micro Devices, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005004/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom